Results From the CheckMate 143 Clinical Trial: Stalemate or New Game Strategy for Glioblastoma Immunotherapy?
JAMA Oncol
.
2020 Jul 1;6(7):987-989.
doi: 10.1001/jamaoncol.2020.0857.
Authors
Yagmur Muftuoglu
1
,
Linda M Liau
1
Affiliation
1
Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles.
PMID:
32437542
DOI:
10.1001/jamaoncol.2020.0857
No abstract available
Publication types
Editorial
Comment
MeSH terms
Bevacizumab
Glioblastoma* / therapy
Humans
Immunotherapy
Neoplasm Recurrence, Local
Nivolumab
Substances
Bevacizumab
Nivolumab